US Patent Issued to OSSIANIX on May 13 for "Transferrin receptor (TFR)-selective binding peptides capable of crossing the blood brain barrier, encoding nucleic acids thereof and methods of use thereof" (British, American Inventors)

ALEXANDRIA, Va., June 12 -- United States Patent no. 12,297,286, issued on May 13, was assigned to OSSIANIX INC. (Philadelphia).

"Transferrin receptor (TFR)-selective binding peptides capable of crossing the blood brain barrier, encoding nucleic acids thereof and methods of use thereof" was invented by Pawel Stocki (Royston, Great Britain), Krzysztof Bartlomiej Wicher (Cambridge, Great Britain), Jaroslaw Michal Szary (Stevenage, Great Britain) and Julia Lynn Rutkowski (Bryn Mawr, Pa.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to the fields of molecular medicine and targeted delivery of therapeutic or diagnostic agents to cells outside the vascular system and into the parench...